Market Cap 2.01B
Revenue (ttm) 714.73M
Net Income (ttm) 145.49M
EPS (ttm) N/A
PE Ratio 13.56
Forward PE 11.15
Profit Margin 20.36%
Debt to Equity Ratio 0.24
Volume 652,200
Avg Vol 635,900
Day's Range N/A - N/A
Shares Out 57.42M
Stochastic %K 46%
Beta 0.84
Analysts Strong Sell
Price Target $50.27

Company Profile

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 c...

Industry: Biotechnology
Sector: Healthcare
Phone: 484 539 9800
Address:
630 West Germantown Pike, Suite 215, Plymouth Meeting, United States
FinJay
FinJay Aug. 7 at 4:18 AM
$HRMY https://youtu.be/xRci-OxqkYI
0 · Reply
Gmiddel
Gmiddel Aug. 6 at 2:32 PM
$HRMY Wondering if anyone has more insight into this company that can explain the following: HRMY has a P/E of ~11-11.5 right now. With 3-5 yr EPS growth rate of 15%, their PEG ratio would be 0.733 - 0.766. Very good. The current analyst growth forecasts I see are closer to 30-40%. So even if their growth is 15% - less than half of what analysts expect, and they severely under deliver, their PEG is still well below 1. Their net cash-debt per share is $6.7 and increasing, so that shouldn't be holding the price back. Their FCF per share is $4.4 and increasing, so that shouldn't be holding the price back. Their ROIC is 16.5% which is good on it's own, and has been improving for >4 quarters, fairly stable in the long term - that shouldn't be holding the price back. Their gross margins, operating margins, and profit margins are all very good and increasing over the last ~4 quarters, stable long term - those shouldn't be holding the price back. Anyone have an idea? Is it just industry risk?
2 · Reply
Doozio
Doozio Aug. 5 at 8:50 PM
$XBI has gotten its RYTM and they supported it in $HRMY as da $HALO gaps n GOGO’s to protect YO as its about to get fookin $LGND ary NEXT as the 🧠 spreads 🐒🍌🧠⏰♾️
0 · Reply
TwoToesTrading
TwoToesTrading Aug. 5 at 7:02 PM
0 · Reply
WallStJesus
WallStJesus Aug. 5 at 7:01 PM
$HRMY OCT DIP BUYER IN THE PHARMA PLAY
0 · Reply
detwin
detwin Aug. 5 at 12:50 PM
$HRMY yeah, pre-market move might be irrational or "sell on good news" or whatever other bs exists. I don't see a big sell reason
0 · Reply
CrispDry
CrispDry Aug. 5 at 12:43 PM
$HRMY being down pre market makes no sense at all
0 · Reply
OpenOutcrier
OpenOutcrier Aug. 5 at 12:39 PM
$HRMY (-8.3% pre) Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025 https://ooc.bz/l/72609
0 · Reply
Estimize
Estimize Aug. 5 at 12:00 PM
$HRMY reported 0.92 EPS and 200.49 revenue for Q2. http://www.estimize.com/intro/hrmy?chart=historical&metric_name=eps&utm_content=HRMY&utm
0 · Reply
BigSqueezeComing
BigSqueezeComing Aug. 5 at 11:38 AM
$HRMY pt 40
0 · Reply
Latest News on HRMY
Harmony Biosciences: A Compelling Risk-Reward Opportunity

Mar 24, 2025, 12:09 PM EDT - 4 months ago

Harmony Biosciences: A Compelling Risk-Reward Opportunity


FinJay
FinJay Aug. 7 at 4:18 AM
$HRMY https://youtu.be/xRci-OxqkYI
0 · Reply
Gmiddel
Gmiddel Aug. 6 at 2:32 PM
$HRMY Wondering if anyone has more insight into this company that can explain the following: HRMY has a P/E of ~11-11.5 right now. With 3-5 yr EPS growth rate of 15%, their PEG ratio would be 0.733 - 0.766. Very good. The current analyst growth forecasts I see are closer to 30-40%. So even if their growth is 15% - less than half of what analysts expect, and they severely under deliver, their PEG is still well below 1. Their net cash-debt per share is $6.7 and increasing, so that shouldn't be holding the price back. Their FCF per share is $4.4 and increasing, so that shouldn't be holding the price back. Their ROIC is 16.5% which is good on it's own, and has been improving for >4 quarters, fairly stable in the long term - that shouldn't be holding the price back. Their gross margins, operating margins, and profit margins are all very good and increasing over the last ~4 quarters, stable long term - those shouldn't be holding the price back. Anyone have an idea? Is it just industry risk?
2 · Reply
Doozio
Doozio Aug. 5 at 8:50 PM
$XBI has gotten its RYTM and they supported it in $HRMY as da $HALO gaps n GOGO’s to protect YO as its about to get fookin $LGND ary NEXT as the 🧠 spreads 🐒🍌🧠⏰♾️
0 · Reply
TwoToesTrading
TwoToesTrading Aug. 5 at 7:02 PM
0 · Reply
WallStJesus
WallStJesus Aug. 5 at 7:01 PM
$HRMY OCT DIP BUYER IN THE PHARMA PLAY
0 · Reply
detwin
detwin Aug. 5 at 12:50 PM
$HRMY yeah, pre-market move might be irrational or "sell on good news" or whatever other bs exists. I don't see a big sell reason
0 · Reply
CrispDry
CrispDry Aug. 5 at 12:43 PM
$HRMY being down pre market makes no sense at all
0 · Reply
OpenOutcrier
OpenOutcrier Aug. 5 at 12:39 PM
$HRMY (-8.3% pre) Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025 https://ooc.bz/l/72609
0 · Reply
Estimize
Estimize Aug. 5 at 12:00 PM
$HRMY reported 0.92 EPS and 200.49 revenue for Q2. http://www.estimize.com/intro/hrmy?chart=historical&metric_name=eps&utm_content=HRMY&utm
0 · Reply
BigSqueezeComing
BigSqueezeComing Aug. 5 at 11:38 AM
$HRMY pt 40
0 · Reply
BigSqueezeComing
BigSqueezeComing Aug. 5 at 11:37 AM
$HRMY Harmony is on track to announce topline data from its Phase 3 registrational RECONNECT trial of ZYN002 in Fragile X syndrome in Q3 202
0 · Reply
BigSqueezeComing
BigSqueezeComing Aug. 5 at 11:36 AM
$HRMY https://www.businesswire.com/news/home/20250805616991/en/Harmony-Biosciences-Reports-Strong-Q2-2025-Financial-Results-and-Reaffirms-2025-Revenue-Guidance-On-Track-to-Announce-Fragile-X-Topline-Data-From-Phase-3-Registrational-Trial-in-Q3-2025
0 · Reply
dadcashflow
dadcashflow Aug. 1 at 8:09 PM
$HRMY - bio bleed isn't over, waiting for $32 patiently to carry this one.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jul. 31 at 7:30 PM
Attached is a list of all commercial-stage non-oncology focused bios with market caps between $1.5 & $6.0B with recent meaningful approvals since 1/1/2017. FY2028 & 10-year revenue multiples are provided. NOTE: March 31, 2025 cash & debt is used to calculate enterprise values. Aminus ($FOLD) reported Q2 2025 earnings this morning that were slightly ahead of analyst estimates. FOLD trades at one of the lowest multiples of projected revenues in this peer group. $HRMY does as well but we understand HRMY needs a Phase 3 win to manage a near-term patent cliff. $APLS is having a good day after reporting this morning but still trades at multiples on the lower side of this peer group. Of course a low revenue multiple does not mean a bio's share price will increase. $TARS reports Q2 2025 product sales next week. TARS therapy was approved in July of 2023. Non-oncology focused bios that sell within 3 years of FDA approval deliver the highest share price gains (at least back to 1/1/2013). $XBI
0 · Reply
BioTechHealthX
BioTechHealthX Jul. 31 at 2:19 PM
$HRMY Harmony is trading cheap despite soaring WAKIX sales and a growing pipeline. Analysts predict huge upside—don’t miss this biotech breakout. https://biotechhealthx.com/biotech-news/harmony-biosciences-hrmy-could-double-the-shocking-analyst-targets-you-need-to-see/
0 · Reply
Doozio
Doozio Jul. 24 at 10:30 AM
$XBI wen all da $DRUG zzzz go in $RYTM and $HRMY n this gets $LGND ary in 🐒🍌🧠⏰♾️
0 · Reply
BNBComedian
BNBComedian Jul. 23 at 2:23 AM
$HRMY 36 and holding for 5 years now
0 · Reply
Vman66
Vman66 Jul. 22 at 3:06 PM
0 · Reply
JarvisFlow
JarvisFlow Jul. 21 at 12:30 PM
Truist Securities updates rating for Harmony Biosciences Hldgs ( $HRMY ) to Buy, target set at 48.
0 · Reply
FinJay
FinJay Jul. 21 at 3:20 AM
$HRMY https://youtu.be/xRci-OxqkYI
0 · Reply
laziio
laziio Jul. 17 at 1:10 PM
$HRMY $HTOO squeez alert on HTOO
0 · Reply
dadcashflow
dadcashflow Jul. 17 at 1:37 AM
$HRMY - Considering a small exit plan, average around $32S now.
0 · Reply